Literature DB >> 12663768

The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus.

David Warren1, Deborah S Griffin, Celine Mainville, Naomi Rosenberg.   

Abstract

The v-Abl protein tyrosine kinase encoded by Abelson murine leukemia virus (Ab-MLV) induces transformation of pre-B cells in vivo and in vitro and can transform immortalized fibroblast cell lines in vitro. Although the kinase activity of the protein is required for these events, most previously studied mutants encoding truncated v-Abl proteins that lack the extreme carboxyl terminus retain high transforming capacity in NIH 3T3 cells but transform lymphocytes poorly. To understand the mechanisms responsible for poor lymphoid transformation, mutants expressing a v-Abl protein lacking portions of the COOH terminus were compared for their ability to transform pre-B cells. Although all mutants lacking sequences within the COOH terminus were compromised for lymphoid transformation, loss of amino acids in the central region of the COOH terminus, including those implicated in JAK interaction and DNA binding, decreased transformation twofold or less. In contrast, loss of the extreme COOH terminus rendered the protein unstable and led to rapid proteosome-mediated degradation, a feature that was more prominent when the protein was expressed in Ab-MLV-transformed lymphoid cells. These data indicate that the central portion of the COOH terminus is not essential for lymphoid transformation and reveal that one important function of the COOH terminus is to stabilize the v-Abl protein in lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663768      PMCID: PMC152141          DOI: 10.1128/jvi.77.8.4617-4625.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Inhibition of c-Abl tyrosine kinase activity by filamentous actin.

Authors:  P J Woodring; T Hunter; J Y Wang
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

2.  The Abl-related gene (Arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actin.

Authors:  Y Wang; A L Miller; M S Mooseker; A J Koleske
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Carboxyl-terminal determinants of Abelson protein important for lymphoma induction.

Authors:  K Parmar; R C Huebner; N Rosenberg
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

4.  The carboxyl terminus of v-Abl protein can augment SH2 domain function.

Authors:  D Warren; A J Heilpern; K Berg; N Rosenberg
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation.

Authors:  N E Rosenberg; D R Clark; O N Witte
Journal:  J Virol       Date:  1980-12       Impact factor: 5.103

6.  Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens.

Authors:  B Chesebro; K Wehrly; M Cloyd; W Britt; J Portis; J Collins; J Nishio
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

7.  Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule.

Authors:  N Rosenberg; O N Witte
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

8.  Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.

Authors:  V Sexl; R Piekorz; R Moriggl; J Rohrer; M P Brown; K D Bunting; K Rothammer; M F Roussel; J N Ihle
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

9.  Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.

Authors:  C A Mainville; K Parmar; I Unnikrishnan; L Gong; G D Raffel; N Rosenberg
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

10.  A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  8 in total

1.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

2.  Disruption of the Shc/Grb2 complex during abelson virus transformation affects proliferation, but not apoptosis.

Authors:  Linda B Baughn; Naomi Rosenberg
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

4.  IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

Authors:  Mo-Ying Hsieh; Richard A Van Etten
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

5.  Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.

Authors:  Rebekah Stackpole Zimmerman; Naomi Rosenberg
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

6.  Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

Authors:  Shengqing Gu; Wayne W Chan; Golam Mohi; Joel Rosenbaum; Azin Sayad; Zhibin Lu; Carl Virtanen; Shaoguang Li; Benjamin G Neel; Richard A Van Etten
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

7.  Absence of p53 complements defects in Abelson murine leukemia virus signaling.

Authors:  Indira Unnikrishnan; Naomi Rosenberg
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.

Authors:  Chae-ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.